

Acne-Rosacea Effective 01/01/2022				
Plan	☐ MassHealth UPPL ☐ Commercial/Exchange		□ Prior Authorization □ O and the Market	
Benefit	☑ Pharmacy Benefit ☐ Medical Benefit	Program Type	☐ Quantity Limit ☐ Step Therapy	
Specialty Limitations	N/A			
	Medical and Specialty Medications			
Contact	All Plans	Phone: 877-519-1908	Fax: 855-540-3693	
Information	Non-Specialty Medications			
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029	
Exceptions	N/A			

Overview

Prescriptions that meet the initial step therapy requirements will adjudicate automatically at the point of sale. If the prescription does not meet the initial step therapy requirements, the prescription will deny with a message indicating that prior authorization (PA) is required. Refer to the criteria below and submit a PA request for the members who do not meet the initial step therapy requirements at the point of sale.

Initial Step-Therapy Requirements:

First-Line: Medications listed on first-line are covered without prior-authorization.

Second-Line: Second-line medications will pay if the member has filled at least two different first-line medications or a second-line medication within the past 180 days.

Coverage Guidelines

	FIRST-LINE	SECOND-LINE
Medications	Topical Anti-infectives:	Topical Anti-infectives:
for Acne	OTC benzoyl peroxide	Aczone (dapsone) 7.5% gel
Vulgaris	Generic benzoyl peroxide (various	Dapsone 5% gel
	formulations)	
	Generic clindamycin 1%	Topical Retinoids:
	Generic erythromycin 2%	Atralin (tretinoin) 0.05% gel
	Generic sulfacetamide 10% & sulfur 5%	adapalene 0.3% gel (RX)
	Generic sulfacetamide 10%	adapalene 0.1% <u>cream (RX)</u>
		Differin (adapalene) 0.1% <u>lotion</u>
	**Topical Retinoids:	Tazarotene 0.1% cream
	Generic tretinoin cream (0.05% & 0.1%)	Tazorac (tazarotene) 0.05% cream
	Generic tretinoin gel (0.01%, 0.025% & 0.1%)	Tazorac (tazarotene) 0.05% & 0.1% gel
	Differin OTC (adapalene) 0.1% Gel	tretinoin microsphere 0.04%, 0.1% gel
		Fabior (tazarotene) 0.1% aerosol foam

	FIRST-LINE	SECOND-LINE
Medications	Generic metronidazole 0.75% cream, gel,	metronidazole 1% gel
for Acne	lotion	Noritate (metronidazole) 1% cream
Rosacea		azelaic acid 15% gel
		Ivermectin (Soolantra) 1% cream

If a member does not meet the initial step therapy requirements, then approval of a second-line medication will be granted if the member meets the following criteria:

Aczone 7.5% gel & dapsone 5% gel

- 1. Patient must have a diagnosis of acne vulgaris (comedonal acne, cystic acne, etc.) or rosacea AND
- 2. Patient has had a documented inadequate response, side effect, or allergy to at least two (2) different generic topical anti-infective agents used separately or together (i.e., clindamycin, erythromycin, benzoyl peroxide, sulfacetamide, or sodium sulfacetamide/sulfur)

Atralin, adapalene 0.3% gel, adapalene 0.1% cream, Differin 0.1% lotion, tretinoin microsphere 0.04%, 0.1% gel

- 1. Patient must have a diagnosis of ichthyosis, hyperkeratosis, acne vulgaris (comedonal acne, cystic acne, etc.), or rosacea **AND**
- 2. Patient has had a documented inadequate response, side effect, or allergy to a *preferred* generic tretinoin cream or gel OR Differin OTC 0.1% gel.

Tazorac cream/gel 0.05%, Tazorac 0.1% gel, tazarotene 0.1% cream & Fabior foam

- 1. Patient must have a diagnosis of plaque psoriasis **OR**
- 2. Patient must have a diagnosis of acne vulgaris (comedonal acne, cystic acne, etc.), or rosacea AND
- 3. Patient has had a documented inadequate response, side effect, or allergy to a *preferred* generic tretinoin cream or gel OR Differin OTC 0.1% gel.

Azelaic acid 15% Gel, metronidazole 1% and ivermectin 1%

- 1. Patient must have a diagnosis of rosacea AND
- 2. Patient has had a documented inadequate response, side effect, or allergy to generic metronidazole 0.75% gel, lotion, or cream

Limitations

- 1. Initial approvals and reauthorizations will be granted for 12 months.
- 2. All prescriptions for topical Retinoids will require PA for members 26 years of age and older.

References

- 1. Benzoyl peroxide) [prescribing information]. Scottsdale, AZ: ProGen Inc.; received February 2017.
- 2. Erygel (erythromycin) [prescribing information]. Newtown, PA: Prestium Pharma; August 2015
- 3. Plexion (sodium sulfacetamide/sulfur) cleanser [prescribing information]. Houston, TX: Brava Pharmaceuticals LLC; January 2014
- 4. Ovace Plus (sulfacetamide) foam [prescribing information]. San Antonio, TX: Mission Pharmacal Co; January 2015.
- 5. Altreno (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; August 2018.



- 6. Differin Gel 0.1% (adapalene) [prescribing information]. Fort Worth, TX: Galderma; June 2018.
- 7. Aczone 5% Gel (dapsone) [prescribing information]. Irvine, CA: Allergan; May 2018.:
- 8. Avita (tretinoin) gel [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; January 2018.
- 9. Differin Gel 0.3% (adapalene) [prescribing information]. Fort Worth, TX: Galderma; December 2013.
- 10. Differin Lotion (adapalene) [prescribing information]. Fort Worth, TX: Galderma; April 2013.
- 11. Tazorac cream (tazarotene) [prescribing information]. Irvine, CA: Allergan, Inc; July 2017
- 12. Tazorac gel (tazarotene) [prescribing information]. Irvine, CA: Allergan, Inc; April 2018.
- 13. Flagyl Cream (metronidazole) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; August 2018.
- 14. MetroLotion (metronidazole) [prescribing information]. Fort Worth, TX: Galderma Laboratories; February 2017.
- 15. Metronidazole gel [prescribing information]. Bridgewater, NJ: Valeant; March 2014
- 16. Noritate (metronidazole) 1% cream [prescribing information]. Bridgewater, NJ: Valeant; March 2018.
- 17. Finacea (azelaic acid) gel [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; August 2018
- 18. Ivermectin (Soolantra) (ivermectin) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.; April 2018.
- 19. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006; 77:3.
- 20. Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007; 6:495.
- 21. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67:4.

Review History

03/21/05 - Reviewed

02/27/06 - Updated

03/05/07 - Updated

12/20/07 – Updated

010/3/08 - Updated

02/25/08 - Updated

02/23/09 – Updated

09/02/09 - Avita note

02/22/10 - Updated

06/18/10 – Adapalene gel

07/23/10 – Adapalene cr

08/02/10 - Tretin-x

02/28/11 - Reviewed

02/27/12 - Reviewed

02/25/13 – Approvable dx question

04/08/13 - Updated

07/29/13 - Updated

08/26/13 - Updated

10/21/13 - Updated

11/04/13 - Updated

01/13/14 - Retin-A micro gel & Metrogel 1% generics

02/24/14 - Updated

05/05/14 – Differin generic



02/23/15 - Reviewed

09/18/17 - Updated

02/26/18 – Updated

02/20/19 – Updated

07/2019 – Removed references to Finacea foam (nonformulary)

11/18/2020- Removed references to Azelex; removed Azelex from ST criteria to NF for 1/1/2021 strategy for Comm/Exch. Separated out criteria for MH vs. Comm/Exch

11/17/2021- Reviewed and Updated; added Tazorac 0.1% gel to Coverage requirements. Effective 01/01/2022.

